Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome.

ABSTRACT:

Background

We have investigated the use of nebulized surfactant as a potential therapeutic option for the patients with coronavirus disease 2019 (COVID-19)-associated acute respiratory distress syndrome (ARDS) undergoing non-invasive ventilation.

Methods

The patients were divided into 2 groups: surfactant (n = 33) and control (n = 32). The subjects in the surfactant group received the inhaled surfactant at daily dose of 150-300 mg. The oxygenation parameters and several clinical outcomes were analyzed.

Results

On the 5 day of therapy, PaO₂/FiO₂ improved significantly in the surfactant group compared to the control group (184 (155-212) mmHg vs 150 (91-173) mmHg, p = 0.02). The inhaled surfactant significantly reduced the need for transfer of patie

SUBMITTER: Avdeev SN 

PROVIDER: S-EPMC8163691 | biostudies-literature | 2021 Aug-Sep

REPOSITORIES: biostudies-literature